Solvay Pharma Россия и СНГ Обратная связь Карта сайта
Вторник, 27 мая 2008 г.
Сделать стартовойДобавить в избранноеСообщить о странице другуW@PAvantGoPDA
В стремлении к прогрессу, с заботой о людях
Медицинские новости
Медицинские новости


  1. Hypogonadism Task Force. AACE clinical practice guidelines for the evaluation and treatment of hypogonadism in adult male patients. Endocr Pract 1996;2:440-453.
  2. Tenover JL. Male hormone replacement therapy incIuding “andropause.” Endocrinol Metab Clin North Am 1998;27:969-987.
  3. Winters SJ. Current status of testosterone replacement therapy in men. Arch Fam Med 1999;8:257-263.
  4. Handelsman DJ. Testosterone and other androgens: physiology, pharmacology, and therapeutic use. In: DeGroot LJ, et al, eds: Endocrinology. 3rd ed. Philadelphia, Pa: W.B, Saunders Co; 1995:2351-2361.
  5. Wilson JD. Androgens. In: Gilman AG, consulting ed; Hardman JG, Limbird LE, eds-in-chief, Molinoff PB, Ruddon RW, eds. Goodman & Gilman’s The Pharmacologic Basis of Therapeutics. 8th ed. New York, NY: Pergamon Press, Inc., 1990;1413-1430.
  6. Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev 1987;8:1-28.
  7. Bagatell CJ, Bremner WJ. Drug therapy: androgens in men – uses and abuses. N Engl J Med 1996;334:707-714.
  8. Griffin JE, Wilson JD. Disorders of the testes and the male reproductive tract. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds. Williams Textbook of Endocrinology. 9th ed. Philadelphia, Pa: W.B. Saunders Co; 1998:819-875.
  9. Dobs AS. Androgen therapy in AIDS wasting, BailliПre’s Clin Endocrinol Metab 1998;12:379-390.
  10. Maas D, Jochen A, Lalande B. Age-related changes in male gonadal function: implications for therapy. Drugs Aging 1997;11:45-60.
  11. Plymate S. Hypogonadism. Endocrinol Metab Clin North Am 1994;23:749-772.
  12., accessed on May 17,2002.
  13. Francis RM. The effects of testosterone on osteoporosis in men. Clin Endocrinol 1999;50:411-414.
  14. Katznelson L. Therapeutic role of androgens in the treatment of osteoporosis in men. BailliПres Clin Endocrinol Metab 1998;12:453-470.
  15. Bouloux P-MG, Wass JAH. Endocrinology. In: Kirby RS, Carson CC, Webster GD, eds. Impotence: Diagnosis and Management of Male Erectile Dysfunction. Oxford, UK: Butterworth-Heinemann Ltd; 1991:44-54.
  16. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151:54-61.
  17. Harman SM, Metter EJ, Tobin JDF, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001;86:724-731.
  18. Nieschlag E, Behre HM, Pharmacology and clinical uses of testosterone. In: Nieschlag E, Behre HM, eds. Testosterone: Action, Deficiency, Substitution. 2nd ed. Berlin-Heidelberg: Springer-Verlag: 1998:293-328.
  19. Wang C, Swerdloff RS, Androgen replacement therapy. Ann Med 1997;29:365-370.
  20. AndroGel Package lnsert, Unimed Pharmaceuticals, Inc., a company of Solvay Pharmaceuticals, Inc.
  21. Data on file. Unimed Pharmaceuticals, Inc., a company of Solvay Pharmaceuticals, Inc.
  22. Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal gel in hypogonadal men. J Clin Endocrinol Metab 2000;85:4500-4510.
  23. Wang C, Berman N, Longstreth JA, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a general research center study. J Clin Endocrinol Metab 2000;85:964-966.
  24. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000;85:2839-2853.
  25. Wang C, Swerdloff RS, Iranmanesh A, et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol 2001;54:739-750.
  26. Swerdloff RS, Wang C, lranmanesh A, et al. Transdermal testosterone (T) gel is efficacious and safe in older compared to young men. Poster presentation #P2-648 at the 84th Annual Meeting of the Endocrine Society, June 19-22, 2002, San Francisco, CA.
  27. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel®) treatment maintains beneficial effects on sexual function and mood, lean and fat mass and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89:2085-98
  28. Cunningham GR, Swerdloff RS, et al. Summary from the Second Annual Andropause Consensus 2001 Meeting.

Solvay Pharma
Баннерная сеть Солвей-Фарма.ру

Последнее обновление  27.05.2008 г.